Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 1/20 | 0.32 |
| ▸ | HTT | P42858 | 1/20 | 0.32 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.32 |
| ▸ | METAP2 | P50579 | 1/20 | 0.31 |
| ▸ | SMYD2 | Q9NRG4 | 1/20 | 0.31 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.31 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.31 |
| ▸ | KIF11 | P52732 | 3/20 | 0.30 |
| ▸ | CTSK | P43235 | 2/20 | 0.30 |
| ▸ | MTNR1A | P48039 | 2/20 | 0.30 |
| ▸ | MTNR1B | P49286 | 2/20 | 0.30 |
| ▸ | PSMB5 | P28074 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20494817 | 1.00 | CYP3A4 (0.32) | CYP3A4HTTSMN1; SMN2METAP2SMYD2 | |
| SCHEMBL20569784 | 0.91 | SMN1; SMN2 (0.33) | CYP3A4HTTSMN1; SMN2METAP2SMYD2 | |
| SCHEMBL19285641 | 0.91 | SMN1; SMN2 (0.33) | CYP3A4HTTSMN1; SMN2METAP2SMYD2 | |
| SCHEMBL20742878 | 0.91 | SMN1; SMN2 (0.33) | CYP3A4HTTSMN1; SMN2METAP2SMYD2 | |
| SCHEMBL19301049 | 0.89 | ATM (0.41) | CTSK | |
| SCHEMBL28356347 | 0.89 | ATM (0.41) | CTSK | |
| SCHEMBL19285506 | 0.87 | CYP3A4 (0.32) | CYP3A4HTTSMN1; SMN2SMYD2CTSK | |
| SCHEMBL20494607 | 0.87 | CYP3A4 (0.32) | CYP3A4HTTSMN1; SMN2SMYD2CTSK | |
| SCHEMBL20742851 | 0.87 | MTNR1A (0.37) | CYP3A4HTTSMN1; SMN2MTNR1AMTNR1B | |
| SCHEMBL19285544 | 0.87 | MTNR1A (0.37) | CYP3A4HTTSMN1; SMN2MTNR1AMTNR1B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11993571-B2 | Indole derivatives as efflux pump inhibitors | RUTGERS, THE STATE UNIVERSITY OF NEW JERSEY (US) | 2024-05-28 | — | — | US | disclosed |
| US-11180459-B2 | Bacterial efflux pump inhibitors | RUTGERS, THE STATE UNIVERSITY OF NEW JERSEY (US) | 2021-11-23 | — | — | US | disclosed |
| US-20210094912-A1 | INDOLE DERIVATIVES AS EFFLUX PUMP INHIBITORS | RUTGERS, THE STATE UNIVERISTY OF NEW JERSEY (US) | 2021-04-01 | — | — | US | disclosed |
| US-10836706-B2 | Bacterial efflux pump inhibitors | RUTGERS, THE STATE UNIVERSITY OF NEW JERSEY (US) | 2020-11-17 | — | — | US | disclosed |
| US-20200140393-A1 | BACTERIAL EFFLUX PUMP INHIBITORS | RUTGERS, THE STATE UNIVERISTY OF NEW JERSEY (US) | 2020-05-07 | — | — | US | disclosed |
| US-20190055188-A1 | BACTERIAL EFFLUX PUMP INHIBITORS | RUTGERS, THE STATE UNIVERSITY OF NEW JERSEY | 2019-02-21 | — | — | US | disclosed |
| WO-2018165611-A1 | INDOLE DERIVATIVES AS EFFLUX PUMP INHIBITORS | RUTGERS, THE STATE UNIVERSITY OF NEW JERSEY (US) | 2018-09-13 | — | — | WO | disclosed |
| WO-2018165612-A1 | BACTERIAL EFFLUX PUMP INHIBITORS | RUTGERS, THE STATE UNIVERSITY OF NEW JERSEY (US) | 2018-09-13 | — | — | WO | disclosed |
| WO-2017147335-A1 | BACTERIAL EFFLUX PUMP INHIBITORS | RUTGERS, THE STATE UNIVERSITY OF NEW JERSEY (US) | 2017-08-31 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11180459-B2 | Bacterial efflux pump inhibitors | ABCB11, ABCB1, SLC47A1 | CYP3A4 524/4885HTT 4449/4885SMN1; SMN2 4875/4885 |
| US-10836706-B2 | Bacterial efflux pump inhibitors | ABCB11, ABCB1, SLC47A1 | CYP3A4 621/4885HTT 4490/4885SMN1; SMN2 4878/4885 |
| US-20200140393-A1 | BACTERIAL EFFLUX PUMP INHIBITORS | ABCB11, ABCB1, SLC47A1 | CYP3A4 524/4885HTT 4449/4885SMN1; SMN2 4875/4885 |
| US-20210094912-A1 | INDOLE DERIVATIVES AS EFFLUX PUMP INHIBITORS | ABCB11, ABCB1, ABCG2 | CYP3A4 175/4885HTT 3888/4885SMN1; SMN2 4885/4885 |
| US-20190055188-A1 | BACTERIAL EFFLUX PUMP INHIBITORS | ABCB11, ABCB1, SLC47A1 | CYP3A4 621/4885HTT 4490/4885SMN1; SMN2 4878/4885 |
| US-11993571-B2 | Indole derivatives as efflux pump inhibitors | ABCB11, ABCB1, ABCG2 | CYP3A4 175/4885HTT 3888/4885SMN1; SMN2 4885/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.